Buy Stocks Easy | About Us
April 3, 2020
Buy Stocks Easy | Online Stocks

AGIO


Buy Agios Pharmaceuticals, Inc. Stock (symbol: AGIO) Easy Online

Company Name: Agios Pharmaceuticals, Inc.

Symbol: AGIO

Sector: Health Care

Industry: Major Pharmaceuticals

IPO: 2013

AGIO Current Share Price

Today's AGIO ( Agios Pharmaceuticals, Inc. ) opening price: $48.0800

Yesterday's AGIO ( Agios Pharmaceuticals, Inc. ) closing price: $47.9000

Agios Pharmaceuticals, Inc. Stock ( symbol: AGIO ) Price Chart since IPO (2013):

12 Months Agios Pharmaceuticals, Inc. Stock ( symbol: AGIO ) Price Chart

Popular Questions about Agios Pharmaceuticals, Inc. Public Stock ( AGIO )

A: Agios Pharmaceuticals, Inc. stock symbol (also called stock or share ticker) is AGIO

A: Agios Pharmaceuticals, Inc. IPO (Initial Public Offering) took place on 2013

A: Agios Pharmaceuticals, Inc.'s stock (AGIO symbol) price at ther IPO (initial Public Offering) was $48.0800

Q: Is AGIO stock worth buying at the moment?

A: The AGIO stock performance since 2019 are rather disappointing. If you had bought 1 share of Agios Pharmaceuticals, Inc. stock (symbol: AGIO) at the beginning of 2019, at the opening share price of $53.6000, you would be left with exactly $48.0800 - which means a waste of your money and time. - SHOW ONLY IF equal or loose.

Buy Agios Pharmaceuticals, Inc. Stock Easy Online

Agios Pharmaceuticals, Inc. Stock Ticker Price Chart since IPO:





Agios Pharmaceuticals, Inc. Stock Price Yesterday



 


Agios Pharmaceuticals, Inc. Stock Price – Last Week




 


Agios Pharmaceuticals, Inc. Stock Price – Last Month




 


Agios Pharmaceuticals, Inc. Stock Value Chart – 12 Months




            

                

                    

                    
                

                
                
Rate this post

                
            

            
            

             

            

        

    



            



    

        

            

                
 Latest Stock News: 

            

        

        



                            

                    


                        
                            http://www.globenewswire.com/news-release/2019/12/16/1961210/0/en/Agios-Receives-FDA-Breakthrough-Therapy-Designation-for-TIBSOVO-ivosidenib-for-the-Treatment-of-Adult-Patients-with-Relapsed-or-Refractory-Myelodysplastic-Syndrome-with-an-IDH1-Mut.html
                            

                                
Agios Receives FDA Breakthrough Therapy Designation for TIBSOVO® (ivosidenib) for the Treatment of Adult Patients with Relapsed or Refractory Myelodysplastic Syndrome with an IDH1 Mutation

                                
                                
CAMBRIDGE, Mass., Dec.  16, 2019  (GLOBE NEWSWIRE) -- Agios Pharmac...


                            

                        
                    

                


                            

                    


                        
                            http://www.globenewswire.com/news-release/2019/12/09/1957998/0/en/Agios-Presents-Updated-Data-for-Mitapivat-from-Extension-Phase-of-the-DRIVE-PK-Study-in-Patients-with-Pyruvate-Kinase-Deficiency.html
                            

                                
Agios Presents Updated Data for Mitapivat from Extension Phase of the DRIVE PK Study in Patients with Pyruvate Kinase Deficiency

                                
                                
– Robust Hemoglobin Increases Maintained in 18 Patients in the Exte...


                            

                        
                    

                


                            

                    


                        
                            http://www.globenewswire.com/news-release/2019/12/09/1957833/0/en/Agios-Presents-Translational-Data-to-Further-Characterize-the-Role-of-TIBSOVO-ivosidenib-Treatment-in-IDH1-Mutant-Acute-Myeloid-Leukemia-AML.html
                            

                                
Agios Presents Translational Data to Further Characterize the Role of TIBSOVO® (ivosidenib) Treatment in IDH1 Mutant Acute Myeloid Leukemia (AML)

                                
                                
– Combination Therapy with TIBSOVO® and Azacitidine Results in Deep...


                            

                        
                    

                


                            

                    


                        
                            http://www.globenewswire.com/news-release/2019/12/08/1957571/0/en/Agios-Establishes-Proof-of-Concept-for-Mitapivat-in-Non-transfusion-dependent-Thalassemia-Based-on-Preliminary-Phase-2-Results.html
                            

                                
Agios Establishes Proof-of-Concept for Mitapivat in Non-transfusion-dependent Thalassemia Based on Preliminary Phase 2 Results

                                
                                
– Treatment with Mitapivat Induced Hemoglobin Increase of ?1.0 g/dL...


                            

                        
                    

                


                            

                    


                        
                            http://www.globenewswire.com/news-release/2019/12/02/1954619/0/en/Agios-Appoints-Bruce-Car-Ph-D-as-Chief-Scientific-Officer.html
                            

                                
Agios Appoints Bruce Car, Ph.D., as Chief Scientific Officer

                                
                                
CAMBRIDGE, Mass., Dec.  02, 2019  (GLOBE NEWSWIRE) -- Agios Pharmac...


                            

                        
                    

                


                            

                    


                        
                            https://www.fool.com/investing/2019/11/27/agios-pharmaceuticals-raised-294-million-to-fight.aspx
                            

                                
Agios Pharmaceuticals Raised $294 Million to Fight Cancer and Rare Genetic Diseases: What It Means for Investors

                                
                                
The cash will help the biotech get to profitability.


                            

                        
                    

                


                            

                    


                        
                            http://www.globenewswire.com/news-release/2019/11/25/1951861/0/en/Agios-Appoints-Jonathan-Biller-as-Chief-Legal-Officer.html
                            

                                
Agios Appoints Jonathan Biller as Chief Legal Officer

                                
                                
CAMBRIDGE, Mass., Nov.  25, 2019  (GLOBE NEWSWIRE) -- Agios Pharmac...


                            

                        
                    

                


                            

                    


                        
                            http://www.globenewswire.com/news-release/2019/11/22/1951595/0/en/Agios-Presents-New-Pharmacodynamic-and-Response-Data-from-Both-Cohorts-of-the-Perioperative-Study-of-Vorasidenib-and-TIBSOVO-ivosidenib-in-Patients-with-IDH1-Mutant-Positive-Low-Gr.html
                            

                                
Agios Presents New Pharmacodynamic and Response Data from Both Cohorts of the Perioperative Study of Vorasidenib and TIBSOVO® (ivosidenib) in Patients with IDH1 Mutant Positive Low-Grade Glioma

                                
                                
– Preliminary Efficacy Data Show 31% Overall Response Rate for Both...


                            

                        
                    

                


                            

                    


                        
                            http://www.globenewswire.com/news-release/2019/11/13/1946485/0/en/Agios-Announces-Closing-of-Public-Offering-and-Full-Exercise-of-Option-to-Purchase-Additional-Shares.html
                            

                                
Agios Announces Closing of Public Offering and Full Exercise of Option to Purchase Additional Shares

                                
                                
CAMBRIDGE, Mass., Nov.  13, 2019  (GLOBE NEWSWIRE) -- Agios Pharmac...


                            

                        
                    

                


            
        

    




    
    





	
	  

	  All right reserved Buy Stocks Easy , 2019.